UK Pharma’s Bid To Curb NHS Pricing Power Fails In Court
The ABPI decides not to appeal after the High Court rejected what NHS England called 'flawed legal manoeuvres' which the judge said would ‘produce an absurd result.’
You may also be interested in...
New NICE and NHS England appraisal rules regarding timelines and price thresholds could fast-track new cost-effective drugs but then delay them from reaching patients for up to three years. The new regulations, which will come into force in April, have raised a lot of questions around methodology and impact outside of England.
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.